Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2009

01-10-2009 | Invited Commentary

Do GnRH analogs protect against ovarian toxicity of chemotherapy?

Author: Halle C. F. Moore

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Login to get access

Excerpt

Premature ovarian failure is a well described complication of adjuvant chemotherapy for breast cancer. For a variety of reasons, including fertility and quality of life concerns, individuals being treated for breast and other cancers may wish to avoid loss of ovarian function. In this issue of breast cancer research and treatment, Sverrisdottir et al. [1] report on a substudy of ovarian function outcomes following adjuvant therapy with and without goserelin coadministration among patients enrolled in the ZIPP (Zoladex in Premenopausal Patients) trial. …
Literature
1.
Sverrisdottir A, Nystedt M, Johansson H, Fornander T (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat. doi:10.​1007/​s10549-009-0313-5
2.
3.
Moore H (2008) Ovarian failure after chemotherapy for breast cancer and the role of gonadotropin-releasing hormone analogs in protection of ovarian function. Am Soc Clin Oncol Ed Book:39–42
4.
Lee SJ, Schover LR, Partridge AH et al (2006) American society of clinical oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24(18):2917–2931PubMedCrossRef
5.
Ravdin PM, Fritz NF, Tormey DC, Jordan VC (1988) Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen. Cancer Res 48:1026–1029PubMed
Metadata
Title
Do GnRH analogs protect against ovarian toxicity of chemotherapy?
Author
Halle C. F. Moore
Publication date
01-10-2009
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0338-9

Other articles of this Issue 3/2009

Breast Cancer Research and Treatment 3/2009 Go to the issue

Epidemiology

A comprehensive evaluation of outcomes for inflammatory breast cancer

Preclinical Study

Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model

Clinical Trial

The effect of transcutaneous electrical nerve stimulation on postmastectomy skin flap necrosis

Clinical trial

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer

Clinical Trial

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

Invited Commentary

Measuring lymphedema in patients with breast cancer: go with the flow?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits